VBI Vaccines Inc. (VBIV)
- Previous Close
0.5994 - Open
0.5914 - Bid 0.5417 x 100
- Ask 0.6042 x 100
- Day's Range
0.5600 - 0.6000 - 52 Week Range
0.4500 - 3.4700 - Volume
187,618 - Avg. Volume
460,969 - Market Cap (intraday)
16.32M - Beta (5Y Monthly) 1.92
- PE Ratio (TTM)
-- - EPS (TTM)
-6.0300 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
www.vbivaccines.comRecent News: VBIV
Performance Overview: VBIV
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VBIV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VBIV
Valuation Measures
Market Cap
16.32M
Enterprise Value
45.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.03
Price/Book (mrq)
2.17
Enterprise Value/Revenue
5.26
Enterprise Value/EBITDA
-0.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.57%
Return on Equity (ttm)
-258.99%
Revenue (ttm)
8.68M
Net Income Avi to Common (ttm)
-93.84M
Diluted EPS (ttm)
-6.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
23.68M
Total Debt/Equity (mrq)
704.66%
Levered Free Cash Flow (ttm)
-39.41M